Hutchison China Meditech looks to first drug approval this year
AIM-listed cancer drug developer Hutchison China MediTech Limited (LON:HCM) expects this year will see fruquintinib become China’s first approved Tyrosine-Kinase inhibitor (TKI).
TKIs inhibit cancer cells’ ability to adapt and fruquintinib successfully passed a phase III study in colorectal cancer last year.
A new drug application was submitted to China’s Center for Drug Evaluation of the CFDA in June 2017 and is undergoing technical reviews and manufacturing inspections.
Trials using fruquintinib, where Eli Lily is the Chi-Med’s partner, are also underway for gastric cancer and various stages of non-small cell lung cancer.
A second TKI, Savolitinib, is also going through clinical trials as a combination with AstraZeneca’s lung cancer treatments Tagrisso and Iressa.
These drugs are for patients suffering mutations on a gene called EGFR.
All told Chi-Med has six phase III trials either ongoing or enrolling at present and eight in total.
Simon To, chairman, said: “In our Innovation Platform, we have progressed our deep portfolio of eight clinical drug candidates, now in active or completing clinical trials in 36 TPPs around the world.
“Two major milestones were the formal NDA submission for fruquintinib in CRC in China; and the initiation of our first global Phase III registration study of savolitinib in c-MET-driven metastatic PRCC.
“We also presented positive Phase Ib/II data at major scientific conferences on savolitinib in PRCC, NSCLC and gastric cancer; fruquintinib in NSCLC and gastric cancer; sulfatinib in NET and thyroid cancer; and theliatinib in esophageal cancer, all positioning us well for 2018.”
Revenues in 2017 rose by 12% to $241.2mln (2016: US$216.1mln), with a net loss of US$26.7mln (US$11.7mln) afterUS $88mln spent on R&D.
Cash at the year-end was US$480mln after the company raised US$293mln when it joined Nasdaq late last year.
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/192976/hutchison-china-meditech-looks-to-first-drug-approval-this-year-192976.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).